1. Executive summary
2. Research objectives and focus
2.1 Research objectives
2.2 Research focus
3. Current treatment strategies
3.1 Overview
3.2 Dupixent (dupilumab; Sanofi/Regeneron)
3.2.1 Key insights summary
3.2.2 Drug summary
3.3 Eucrisa (crisaborole; Pfizer)
3.3.1 Key insights summary
3.3.2 Drug summary
4. Selected late-stage pipeline programmes
4.1 Tralokinumab (AstraZeneca/Leo Pharma)
4.1.1 Key insights summary
4.1.2 Drug summary
4.2 Lebrikizumab (Dermira)
4.2.1 Key insights summary
4.2.2 Drug summary
4.3 Mepolizumab (Nucala; GSK)
4.3.1 Key insights summary
4.3.2 Drug summary
4.4 Nemolizumab (Galderma/Chugai)
4.4.1 Key insights summary
4.4.2 Drug summary
4.5 ALX-101 (Ralexar Therapeutics)
4.5.1 Key insights summary
4.5.2 Drug summary
4.6 GBR 830 (Glenmark Pharmaceuticals)
4.6.1 Key insights summary
4.6.2 Drug summary
4.7 Tezepelumab (Amgen/AstraZeneca)
4.7.1 Key insights summary
4.7.2 Drug summary
4.8 SB011 (Sterna Biologicals)
4.8.1 Key insights summary
4.8.2 Drug summary
4.9 JAK inhibitors
4.9.1 Key insights summary
4.9.2 Overview
4.9.3 Olumiant (baricitinib; Eli Lilly/Incyte)
4.9.4 PF-04965842 (Pfizer)
4.9.5 Ruxolitinib (Jakavi; Incyte) and Upadacitinib (AbbVie)
5. Other early stage pipeline programmes
5.1 Prostaglandin DP2 receptor antagonists
5.1.2 Fevipiprant (Novartis)
5.2 Galectin 3 inhibitors
5.2.1 GR-MD-02 (Galectin Therapeutics)
5.2.2 ANB020 (AnaptysBio)
6. Evolution of the atopic dermatitis treatment landscape
6.1 Current and future treatment pathways
6.1.2 Key insights summary
7. Future of the atopic dermatitis treatment paradigm
7.1 Concluding remarks
8. Appendix
8.1 KOL details
8.1.1 US KOLs
8.1.2 European KOLs